U.S. Markets close in 1 hr 8 mins

Ironwood Pharmaceuticals, Inc. (IRWD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
17.240+0.240 (+1.412%)
As of 2:52PM EDT. Market open.
People also watch
INFIAEGRMNTASGYPEPZM

Ironwood Pharmaceuticals, Inc.

301 Binney Street
Cambridge, MA 02142
United States
617-621-7722
http://www.ironwoodpharma.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees674

Key Executives

NameTitlePayExercisedAge
Dr. Peter M. Hecht Ph.D.Co-Founder, Chief Exec. Officer and Director108.06k2.76M53
Mr. Thomas GraneyChief Financial Officer and Sr. VP of Fin. & Corp. StrategyN/AN/A52
Dr. Mark G. Currie Ph.D.Chief Scientific Officer, Pres of R&D and Sr. VP763.04k6.08M62
Ms. Halley E. Gilbert Esq.Chief Legal Officer, Sr. VP and Sec.711.04k315.6k47
Mr. Thomas A. McCourtChief Commercial Officer and Sr. VP of Marketing & Sales731.04kN/A60
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Constella name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout under ZURAMPIC and DUZALLO names. It has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in North America, China, Hong Kong, and Macau; and license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, chronic constipation, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Ironwood Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.